Cizutamig Biosimilar Bispecific Antibody (BCMA × CD3) for Research

Cat No.: GMP-Bios-INN-1136

Anti-TNFRSF17/CD269/BCMA/TNFRSF13A therapeutic antibody (Pre-made Cizutamig biosimilar,Bispecific Mixed Domains (L-kappa-H-gamma1_[VH-G1(CH1-h)]_L-kappa)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cizutamig (development codes CN-106/CND-106) is a bispecific antibody targeting B cell maturation antigen (BCMA/TNFRSF17) and CD3. It is developed by EpimAb Biotherapeutics and Candid Therapeutics for cancer and myasthenia gravis. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1136-1mg 1mg
GMP-Bios-INN-1136-10mg 10mg
GMP-Bios-INN-1136-100mg 100mg
GMP-Bios-INN-1136-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Cizutamig biosimilar, Bispecific Mixed Domains (L-kappa-H-gamma1_[VH-G1(CH1-h)]_L-kappa), Anti-TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E Antibody: Anti-TNFRSF17/BCMA/CD269/Tumor necrosis factor receptor superfamily member 17 therapeutic antibody
INN Name Cizutamig
Target TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E
Format Bispecific Mixed Domains (L-kappa-H-gamma1_[VH-G1(CH1-h)]_L-kappa)
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1;G1
VD LC Kappa;Kappa
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Active
100% SI Structure None;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2024
Year Recommended na
Companies EpimAb Biotherapeutics;Candid Therapeutics
Conditions Approved na
Conditions Active Cancer;Myasthenia gravis
Conditions Discontinued na
Production na
Development Tech na